Dr. Michael Henderson, Chief Business Officer of BridgeBio Pharma, talks about how his company is partnering with academia in a novel way to develop important programs that might otherwise be dropped.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.